for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

348.83USD

Change

25.35(+7.84%)

Volume

23,431,397

Today's Range

325.17

 - 

349.45

52 Week Range

54.21

 - 

349.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
323.48
Open
330.90
Volume
23,431,397
3M AVG Volume
258.82
Today's High
349.45
Today's Low
325.17
52 Week High
349.45
52 Week Low
54.21
Shares Out (MIL)
401.53
Market Cap (MIL)
129,886.20
Forward P/E
12.87
Dividend (Yield %)
--

Next Event

Q2 2021 Moderna Inc Earnings Call

Latest Developments

更多

Moderna Says EMA CHMP Adopts Opinion Recommending Authorization For Use Of Co's COVID-19 Vaccine In Adolescents

Moderna's COVID-19 Vaccine Approved For Children Aged 12 To 17 In EU - EMA

EMA Expects Advice On Moderna Vaccine Use For Teens At End Of Next Week

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.56 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

18.7K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

25.134
Price To Earnings (TTM)
257.92
Price To Sales (TTM)
47.54
Price To Book (MRQ)
33.80
Price To Cash Flow (TTM)
203.91
Total Debt To Equity (MRQ)
4.77
LT Debt To Equity (MRQ)
3.60
Return on Investment (TTM)
19.34
Return on Equity (TTM)
8.10

Latest News

Latest News

EU regulator endorses use of Moderna COVID-19 vaccine in teens

Europe's medicines regulator on Friday recommended approving the use of Moderna's COVID-19 vaccine in 12- to 17-year olds, paving the way for it to become the second shot okayed for adolescent use in the European Union.

UPDATE 2-EU regulator weighing mixing COVID-19 vaccines, booster doses

* Says countries may adapt strategies based on available evidence

EU regulator reviewing Moderna COVID shot for auto-immune blood condition

Europe's drug regulator said on Wednesday it had assessed nine cases of an auto-immune blood condition following vaccination with Moderna Inc's COVID-19 shot, but no "clear causal relationship" could be established between the two.

UPDATE 1-Moderna to supply 20 mln doses of COVID-19 vaccine to Argentina

Moderna Inc said on Monday it had signed a supply agreement with the government of Argentina for 20 million doses of its COVID-19 vaccine or its updated variant booster vaccine candidate.

Moderna signs COVID-19 vaccine supply agreement with Argentina

Moderna Inc said on Monday it had signed a supply agreement with the government of Argentina for 20 million doses of its COVID-19 vaccine or its updated variant booster vaccine candidate.

Saudi Arabia approves Moderna's COVID vaccine -state news agency

Saudi Arabia's Food and Drug Authority on Friday approved Moderna Inc's COVID-19 vaccine for use in the kingdom, the state news agency (SPA) said.

EU regulator lists heart condition as possible side effect of mRNA vaccines

Europe's drug regulator on Friday recommended adding heart inflammation as a possible side effect of mRNA COVID-19 vaccines from Pfizer and Moderna and advised people with a history of capillary leak syndrome to avoid getting Johnson & Johnson's coronavirus shot. (Reporting...

Moderna says plant in France begins manufacturing COVID-19 doses

Moderna Inc said on Thursday that contract manufacturer Recipharm had begun making the company's COVID-19 vaccine at its manufacturing site in France after gaining approval from Europe's drugs regulator. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)

UPDATE 5-India's Cipla gets nod to distribute partner Moderna's COVID vaccine

Indian drugmaker Cipla Ltd has received regulatory approval to distribute partner Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday, clearing the way for the shot to be imported.

UPDATE 2-Moderna's COVID-19 vaccine shows promise against Delta variant in lab study

Moderna Inc's COVID-19 vaccine showed promise against the Delta variant first identified in India in a lab study, with a modest decrease in response compared to the original strain, the drugmaker said on Tuesday.

Moderna's COVID-19 vaccine shows promise against Delta variant in lab study

Moderna Inc said on Tuesday its COVID-19 vaccine produced neutralizing antibodies against emerging variants, including the delta variant first identified in India, in a lab study.

FACTBOX-Countries vaccinating children against COVID-19

Moderna is seeking a green light for using its COVID-19 vaccine for teens as young as 12 in the EU, United States and Canada, as Pfizer - whose shot is already being administered - plans tests on even younger children.

Moderna SE Asia partner says regional vaccine supplies booked to year-end

Zuellig Pharma, Moderna Inc's supply partner for COVID-19 vaccines in Southeast Asia, said on Tuesday that regional orders for the mRNA vaccine were almost fully booked for this year.

Sanofi to invest 400 million euros in a mRNA vaccines facility

Sanofi said it will invest about 400 million euros ($476.4 million) in research and development of next-generation vaccines using mRNA technologies, which proved their efficiency in the Pfizer and Moderna COVID-19 vaccines.

Germany expects faster Moderna COVID-19 vaccine deliveries

Germany expects drugmaker Moderna Inc to deliver COVID-19 vaccines faster than expected, helping it ramp up vaccinations in coming months, the health ministry said on Sunday.

U.S. panel to review heart inflammation cases after Pfizer, Moderna vaccines

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are set to meet on Wednesday to assess the possibility of a link between rare cases of heart inflammation and the mRNA COVID-19 vaccines from Pfizer and partner BioNTech and from Moderna.

UPDATE 2-EU takes up option to buy 150 million more Moderna COVID-19 shots

The European Union has decided to take up an option under a supply contract with drugmaker Moderna that allows the bloc to order 150 million additional COVID-19 vaccines produced by the U.S. biotech firm, the EU Commission said on Tuesday.

Study testing Moderna vaccine in transmission prevention to include young adults

U.S. scientists are expanding a government-funded study that aims to directly answer the question of whether Moderna Inc's COVID-19 vaccine curbs the spread of SARS-CoV-2.

EU takes up option to buy 150 million more Moderna COVID-19 vaccines

The European Union has decided to take up an option under a supply contract with drugmaker Moderna that allows the bloc to order 150 million additional COVID-19 vaccines produced by the U.S. biotech firm, the EU Commission said on Tuesday.

Moderna plans to expand COVID-19 vaccine production: WSJ

Moderna Inc is adding two new production lines at its COVID-19 vaccine manufacturing plant in Massachusetts, in a bid to prepare for making more booster shots, the Wall Street Journal reported on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up